Literature DB >> 32074487

The coronavirus (COVID-19) epidemic and patient safety.

Dirk M Elston1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32074487      PMCID: PMC7134498          DOI: 10.1016/j.jaad.2020.02.031

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
In this issue of the JAAD, Chen et al discuss patient safety measures in a Chinese dermatology clinic during the coronavirus outbreak (2019-nCoV acute respiratory disease), including patient screening, respiratory precautions, and telemedicine consultations. The steps they enacted serve as a reminder that we should have policies in place for infection control in every dermatology clinic. Patients with varicella, measles, and other viral exanthems present to the dermatologist and may pose a risk to patients and office staff. Employees should receive all appropriate vaccinations, and testing should be available for employees to determine their immune status. This is especially important for women of child-bearing age who may be exposed to diseases such as varicella and erythema infectiosum. If available, a negative pressure room should be designated as an isolation room for patients with respiratory pathogens, and exposed susceptible individuals should be furloughed during the incubation period. , Large health care organizations often address these issues during in-processing of employees, but many dermatologists practice in private clinics and should review existing policies to prepare for the inevitability of contagious patients entering the clinic. This is not the first outbreak of a severe coronavirus. Prior outbreaks of virulent coronavirus strains have also been associated with severe respiratory syndromes and patient deaths. Individuals who are asymptomatic or who have only mild symptoms may spread the virus. However, superspreading events—instances where an index patient transmitted disease to ≥5 subsequent patients—were typically associated with patients who were severely ill, initially not recognized as severe respiratory syndrome-coronavirus cases, and subsequently died. Delays in implementation of control measures contributed to secondary transmission, but contact tracing, testing, employee furloughing, and implementation of recommended transmission-based precautions for suspected cases ultimately halted transmission. Our responsibility for patient and employee safety is not limited to respiratory pathogens. Virulent streptococcal infections associated with necrotizing fasciitis and death have been spread during liposuction in outpatient facilities. The procedures were performed by a single surgical team that traveled between locations, and 2 team members were colonized by the organism. Substandard infection control, including errors in equipment sterilization and standard precautions, contributed to the outbreak. Prevention of transmission of blood-borne infections deserves special mention, and readers should review the JAAD continuing medical education articles that focused on patient safety and blood-borne pathogens (https://www.jaad.org/article/S0190-9622(09)00603-3/fulltext and https://www.jaad.org/article/S0190-9622(09)00602-1/fulltext).6, 7, 8 Standard precautions should be enforced, and policies should be in place for postexposure prophylaxis. As captains of our individual ships, it falls to us to put policies in place to prevent the spread of disease and prepare for the needle-stick injuries and transmissible diseases that are part of the practice of medicine.
  8 in total

1.  Nosocomial varicella: worth preventing, but how?

Authors:  S R Preblud
Journal:  Am J Public Health       Date:  1988-01       Impact factor: 9.308

2.  Invasive group A Streptococcus infections associated with liposuction surgery at outpatient facilities not subject to state or federal regulation.

Authors:  Amanda L Beaudoin; Lauren Torso; Katherine Richards; Maria Said; Chris Van Beneden; Allison Longenberger; Stephen Ostroff; Joyanna Wendt; Kathleen Dooling; Matthew Wise; David Blythe; Lucy Wilson; Mària Moll; Joseph F Perz
Journal:  JAMA Intern Med       Date:  2014-07       Impact factor: 21.873

Review 3.  Managing sharps injuries and other occupational exposures to HIV, HBV, and HCV in the dermatology office.

Authors:  Jerry D Brewer; Dirk M Elston; Allison T Vidimos; Stacey A Rizza; Stanley J Miller
Journal:  J Am Acad Dermatol       Date:  2017-08-31       Impact factor: 11.527

Review 4.  Infection control in the outpatient setting.

Authors:  L A Herwaldt; S D Smith; C D Carter
Journal:  Infect Control Hosp Epidemiol       Date:  1998-01       Impact factor: 3.254

Review 5.  Patient safety: Part II. Opportunities for improvement in patient safety.

Authors:  Dirk M Elston; Erik Stratman; Hillary Johnson-Jahangir; Alice Watson; Susan Swiggum; C William Hanke
Journal:  J Am Acad Dermatol       Date:  2009-08       Impact factor: 11.527

Review 6.  Patient safety: Part I. Patient safety and the dermatologist.

Authors:  Dirk M Elston; James S Taylor; Brett Coldiron; Antoinette F Hood; Sandra I Read; Jack S Resneck; Robert S Kirsner; John C Maize; Sabra Sullivan; John Laskas; C William Hanke
Journal:  J Am Acad Dermatol       Date:  2009-08       Impact factor: 11.527

7.  Scope and extent of healthcare-associated Middle East respiratory syndrome coronavirus transmission during two contemporaneous outbreaks in Riyadh, Saudi Arabia, 2017.

Authors:  Khalid H Alanazi; Marie E Killerby; Holly M Biggs; Glen R Abedi; Hani Jokhdar; Ali A Alsharef; Mutaz Mohammed; Osman Abdalla; Aref Almari; Samar Bereagesh; Sameh Tawfik; Husain Alresheedi; Raafat F Alhakeem; Ahmed Hakawi; Haitham Alfalah; Hala Amer; Natalie J Thornburg; Azaibi Tamin; Suvang Trivedi; Suxiang Tong; Xiaoyan Lu; Krista Queen; Yan Li; Senthilkumar K Sakthivel; Ying Tao; Jing Zhang; Clinton R Paden; Hail M Al-Abdely; Abdullah M Assiri; Susan I Gerber; John T Watson
Journal:  Infect Control Hosp Epidemiol       Date:  2019-01       Impact factor: 3.254

8.  What are we doing in the dermatology outpatient department amidst the raging of the 2019 novel coronavirus?

Authors:  Yusha Chen; Sushmita Pradhan; Siliang Xue
Journal:  J Am Acad Dermatol       Date:  2020-02-17       Impact factor: 11.527

  8 in total
  7 in total

1.  Gynecology and women's health care during the COVID-19 pandemic: Patient safety in surgery and prevention.

Authors:  José Maria Soares-Júnior; Isabel C E Sorpreso; Eduardo Vieira Motta; Edivaldo Massazo Utiyama; Edmund Chada Baracat
Journal:  Clinics (Sao Paulo)       Date:  2020-06-22       Impact factor: 2.365

2.  Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies.

Authors:  Rosa Falcone; Giorgio Grani; Valeria Ramundo; Rossella Melcarne; Laura Giacomelli; Sebastiano Filetti; Cosimo Durante
Journal:  Front Oncol       Date:  2020-06-23       Impact factor: 6.244

3.  Network Pharmacology and Bioinformatics Analysis Identifies Potential Therapeutic Targets of Paxlovid Against LUAD/COVID-19.

Authors:  Wentao Zhang; Zhe Yang; Fengge Zhou; Yanjun Wei; Xiaoqing Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-08       Impact factor: 6.055

4.  Safety measures in dermatology help minimize spread of COVID-19.

Authors:  Andy Goren; Dipali Rathod; George Kroumpouzos; Mohammad Jafferany; Mohamad Goldust
Journal:  Dermatol Ther       Date:  2020-07-07       Impact factor: 3.858

5.  Cyclosporine therapy during the COVID-19 pandemic.

Authors:  Lidia Rudnicka; Paulina Glowacka; Mohamad Goldust; Mariusz Sikora; Marta Sar-Pomian; Adriana Rakowska; Zbigniew Samochocki; Malgorzata Olszewska
Journal:  J Am Acad Dermatol       Date:  2020-05-04       Impact factor: 11.527

6.  COVID-19 with dermatologic manifestations and implications: An unfolding conundrum.

Authors:  Nawaf Almutairi; Robert A Schwartz
Journal:  Dermatol Ther       Date:  2020-07-01       Impact factor: 3.858

Review 7.  Covid-19 pandemic and the skin.

Authors:  Kossara Drenovska; Enno Schmidt; Snejina Vassileva
Journal:  Int J Dermatol       Date:  2020-09-21       Impact factor: 3.204

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.